Recent Posts
- AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
- AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment
- AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
Recent Comments
No comments to show.